Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease?

Abstract

Monoclonal antibodies that target immune checkpoints are undoubtedly changing the therapeutic landscape of different human malignancies. Here we comment on the effects of blocking cytotoxic T lymphocyte-associated protein 4 (CTLA4) by means of the monoclonal antibody tremelimumab in patients with refractory malignant mesothelioma, a deadly disease with no… (More)

Topics

Statistics

0204060201520162017
Citations per Year

Citation Velocity: 8

Averaging 8 citations per year over the last 3 years.

Learn more about how we calculate this metric in our FAQ.

Cite this paper

@article{Calabr2014ImmuneCB, title={Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease?}, author={Luana Calabr{\`o} and Michele Di Maio}, journal={Oncoimmunology}, year={2014}, volume={3 1}, pages={e27482} }